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We describe a cohort of Home Parenteral Nutrition (HPN) patients with advanced cancer in order to identify 
factors affecting prognosis. Demographic, anthropometric, biochemical and medical factors, Karnofsky 
Performance Status (KPS), Glasgow Prognostic Score (GPS), and PN requirements were recorded. Univariate 
and multivariate analyses were performed including Kaplan-Meier curves, Cox Regression and correlation 
analyses. In total, 107 HPN patients (68 women, 39 men, mean age 57 years) with advanced cancer were 
identified. The main indications for HPN were bowel obstruction (74.3%) and high output ostomies (14.3%). 
Cancer cachexia was present in 87.1% of patients. The hazard ratio (HR) for upper gastrointestinal and ‘other’ 
cancers vs gynaecological malignancy was 1.75 (p=0.077) and 2.11 (p=0.05), respectively. KPS score, GPS, 
PN volume and PN potassium levels significantly predicted survival (HRKPS≥50 vs <50=0.47; HRGPS=2 vs 
GPS=0=3.19). In multivariate analysis, KPS and GPS remained significant predictors (p<0.05), whilst PN 
volume reached borderline significance (p=0.094). Survival was not significantly affected by the presence of 
metastatic disease, previous or concurrent surgery, chemo-radiotherapy, or indication for HPN (p>0.05). Most 
patients passed away in their homes or hospice (77.9%). Performance status, prognostic scoring and PN 
requirements may predict survival in patients with advanced cancer receiving HPN. 
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Artificial nutrition may be indicated in malnourished oncology patients who cannot autonomously meet their 
nutritional requirements (1). In the last decade there has been an increased trend in referrals and this cohort 
currently represent the commonest indication for home parenteral nutrition (HPN) worldwide. Nevertheless, 
the use of long-term HPN in advanced/incurable (previously referred to as palliative) cancer patients remains 
controversial in the UK (1-6). Timely commencement of HPN is considered in advanced cancer patients with 
an acceptable quality of life who would die from malnutrition-related complications (and in some cases 
starvation) before tumour progression (3, 5, 7). Cachexia is prevalent in more than 50% of patients with 
advanced cancer and can lead to death in more than 10% of subjects (8-10). 
Discrepancies in worldwide clinical practice relate to financial and ethical issues, differing clinician views, 
socio-cultural attitudes and religious beliefs. Appropriate and careful selection of patients to offer HPN is a 
crucial point for clinicians. It is generally accepted that HPN should not be considered in imminently dying 
patients. However, other cases are less clear and robust criteria and guidelines are lacking. Financially, it is 
difficult to estimate direct and indirect costs of HPN services considering the variation between countries. 
Nevertheless, many advocate that its use in this patients’ cohort constitutes an unacceptable additional burden 
to already overstretched health economies (2, 4-6, 11). Finally, there is a paucity of high quality evidence 
about the true impact of HPN on survival, tumour progression, performance status and quality of life to guide 
clinical practice in advanced cancer, as randomised controlled trials would be unethical (2, 4-6, 11, 12). 
Prevalence of HPN in patients with advanced cancers throughout the world reflects differing practices (2, 6, 
13-15). For example, in Denmark and the UK the prevalence is less than 10% while Netherlands, Italy and 
the USA are greater than 50% (2, 5-7, 11, 16, 17). The European Society for Clinical Nutrition and Metabolism 
(ESPEN) guidelines (Grade C) suggest considering HPN in advanced cancer patients with intestinal failure if 
enteral nutrition is insufficient to meet nutritional requirements; expected survival due to tumour progression 
is over two to three months; it is expected that PN will stabilise or improve performance status and/or quality 
of life; and the patient desires PN (1, 7). The commonest indication for HPN in patients with advanced cancer 
is bowel obstruction, caused by intra- or extra-abdominal malignancy with intraperitoneal spread, which is 
usually subacute (1, 6). Although contentious, HPN may facilitate survival and augment the effectiveness of 
palliative chemo-radiotherapy. However, some authors contend that HPN is a burden to patients and possibly 
feeds the tumour (2, 6, 18). 
Robust practical guidance is lacking in advanced cancer patients on HPN despite previous studies 
investigating prognostic factors (2, 3, 6, 13, 19-28). In the present study, we aim to examine the prognostic 
significance of performance status, type and site of tumour, previous or concurrent chemo-radiotherapy, 
anthropometric characteristics, nutritional and inflammatory status, demographic characteristics, serum 
biochemistry and prognostic indices based on a large cohort of patients with advanced cancer receiving HPN 




UCLH is a 665-bed tertiary hospital in central London, UK, and a national referral centre for many types of 
cancer. HPN candidates were initially identified by primary teams (oncology, gynaecology, urology, 
gastroenterology, surgery) and referred to the multi-disciplinary Nutrition Support Team. In each case, the 
options and prognosis were carefully reviewed and discussed with the primary team and patient before 
initiating HPN. Follow-up was performed regularly (every 4-6 weeks) and as clinically relevant.  





All adult patients, 18 years or older, with advanced cancer discharged on HPN from UCLH from 1st of January 
2006 to 15th of October 2016 were included in the analysis. Loss to follow-up was the single exclusion 
criterion. Data was collected retrospectively through UCLH electronic patients’ records and the HPN 
databases held by the Nutrition Support team.  
Data Collection 
The following data were collected:  
Demographics and Medical Factors: primary malignancy, presence of metastases (defined as disease at 
nonadjacent organs), surgery for malignancy, chemotherapy and/or radiotherapy before or during PN, main 
indication for HPN and the place of death. 
HPN Requirements: duration of HPN, volume, nitrogen, glucose, lipid and lipid formulation, electrolytes and 
days per week of HPN. Patients received individualised formulae containing fluids, amino acids, glucose, 
lipids, minerals and trace elements.  
Serum Biochemistry: C-Reactive Protein (CRP), white cell count (WCC), albumin, haemoglobin, sodium, 
potassium, magnesium, phosphate and adjusted calcium.  
Performance Status: Karnofsky Performance Status (KPS) was assessed by the attending clinician and a score 
of 50 was used as cut-off for analyses, with over 50 indicating that the patient is unable to work but able to 
live at home and care for most personal needs with varying amount of assistance needed (29, 30). 
Prognostic Scoring: Glasgow Prognostic Score (GPS) was calculated and is based on the serum levels of 
albumin and CRP. A score of 2 is allocated when both an elevated CRP level (>10 mg/L) and 
hypoalbuminemia (<35 g/L) are present (31). 
Anthropometric Characteristics: Habitual body weight, height, habitual BMI, weight upon starting PN, 
percentage of weight loss when PN commenced (from usual weight), BMI when PN commenced, weight at 
follow-up outpatient appointments at 3 and 6 months after discharge. Patients were defined as having cancer 
cachexia if weight loss > 5% (in absence of simple starvation) was reported or BMI < 20 kg/m2 and any degree 
of weight loss > 2% (32). 
Timeline: The day that HPN started (i.e. discharge date or baseline date) was considered as the starting time 
point for all measurements including anthropometrics, blood tests, and HPN requirements. End time point was 
date of death or censoring date (15 October 2016). Survival was reported in weeks.  
Ethical Considerations 
Individual patient data were anonymized and regulatory approval was granted by the site institutional review 
board. This study involved the collection of existing data and records. Informed consent was exempted 
according to the decision of institutional ethics board committees. This is a retrospective study and adherence 
to the principles of the Declaration of Helsinki was followed during design and analysis. 
Statistical Analysis 
Data are presented as mean and standard deviation (SD) or median and interquartile range (IQR) for 
continuous data and absolute and relative frequency for categorical data, respectively. Overall survival was 
calculated from the onset of HPN until death irrespective of cause or censoring date on 15 October 2016. 
Univariate analyses were conducted with chi-square test, Spearman’s rho for correlations, t-tests and ANOVA. 
After Kaplan-Meier analysis on the impact of the variables on survival, the groups were compared with the 
log-rank test. Variables that showed a p-value of ≤ 0.05 in the univariate analysis were included into Cox 
regression analyses. A p-value ≤ 0.05 was considered significant. For data analysis, IBM SPSS Statistics 
(Release 22.0.0. 2010, Chicago (IL), USA: SPSS, Inc., an IBM Company) was used.  
 






Demographics and Medical Factors. Our sample included 107 patients (68 females, 39 males) with mean age 
57 ± 12 years. Malignancy types and frequencies are shown in Table 2. Most patients had metastatic disease 
(81.3%) and had undergone surgery for their malignancy (79 %), or chemotherapy before and/or during PN 
administration (90.4 %). The majority of patients were radiotherapy naive (71.2 %). Most patients passed 
away in their homes or hospice (77.9 %) (Table 1). 
HPN characteristics. The majority of patients had solely HPN (97.1 %), while 3 % required additional 
intravenous fluids. Median duration of HPN was 12.9 weeks (5.6-29.0). The main indications for HPN were 
bowel obstruction (74.3 %) and high output ostomies (14.3 %). The majority of patients were PN-dependent 
until death (Table 1). Average HPN requirements are shown in Table 3.  
Anthropometrics. Mean BMI was 19.9 ± 4.1 kg/m2 with 41.8% of patients being underweight BMI ≤ 18.5 
kg/m2). Documented weight loss was greater than 10 % and 30 % in 58.1 % and 11.3 % of patients, 
respectively. Cancer cachexia was present in 87.1 %. Mean weight on discharge was 55.3 ± 12.3 kg with a 
relative increase up to 58.6 ± 11.3 kg at 6 months in the outpatient setting (Table 1).  
Performance status and prognostic score. Mean KPS score was 50 ± 16; 66 % of patients scored KPS 50 to 
80. GPS was 2 for most patients (34.6 %) (Table 1). 
Serum Biochemistry. On discharge, mean CRP was high at 46 ± 48.3 mg/L (normal range 0-5.0) with normal 
WCC (9.6 ± 6.8 x 109/L, normal range 3.0-10.0) and albumin borderline low at 32.2 ± 6 g/L (normal range 
34-50). Mean haemoglobin was slightly below normal (101.6 ± 15 g/L, normal range 115-155) and mean 
values of electrolytes were within normal values (Table 1). 
 
Table 1. Patient Characteristics. 
Variables Results 
General Characteristics  
Age (years)*  
≤ 35 3 (2.8) 
36 – 49   24 (22.4) 
50 – 64  48 (44.9) 
65 – 79  30 (28) 
≥ 80  2 (1.9) 
Gender* 
 
Female 68 (63.6) 
Male 39 (36.4) 
Type of malignancy*,†  
Gynaecological  37 (34.6) 
Upper Gastrointestinal 21 (19.6) 
Lower Gastrointestinal 24 (22.4) 
Hepato-pancreatobiliary  10 (9.3) 
Haematological  5 (4.7) 
Other 10 (9.3) 
GPS*  
0 10 (9.3) 
1 19 (17.8) 





2 37 (34.6) 
Not available (n/a) 41 (38.3) 
HPN Characteristics  
HPN Indication*  
Bowel Obstruction 78 (74.3) 
High Output Ostomy 15 (14.3) 
Other‡ 12 (11.4) 
HPN days per week*  
4 5 (4.7) 
5 2 (1.9) 
7 100 (93.4) 
PN lipid type*  
SMOF 34 (38.2) 
Other§ 55 (61.8) 
HPN termination reason*  
Death 93 (94.9) 
Established on oral / enteral feeding 4 (4.1) 
Patient declined 1 (1) 
Anthropometrics  
Usual weight (kg)¶  65.3 ± 14.6 (n = 65) 
Height (m)¶  1.7 ± 0.1 (n = 71) 
Usual BMI (kg/m2)¶  23.5 ± 4.8 (n = 63) 
Weight upon starting PN (kg)¶  55.3 ± 12.3 (n = 71) 
% weight loss upon starting PN¶  15.2 ± 11.5 (n = 62) 
% weight loss upon starting HPN*  
< 20% 42 (67.7) 
20% – 30%  13 (21) 
> 30% 7 (11.3) 
BMI upon starting PN (kg/m2)¶  19.9 ± 4.1 (n = 67) 
Weight in outpatient clinic, 0-3 months (kg)¶) 54.5 ± 9 (n = 37 
Weight in outpatient clinic, 3-6 months (kg)¶  58.6 ± 11.3 (n = 19) 
Serum Biochemistry  
Sodium (mmol/L, 135-145)¶ 136 ± 4 (n = 66) 
Potassium (mmol/L, 3.5-5.1)¶ 4.4 ± 0.5 (n = 66) 
Magnesium (mmol/L, 0.60-1.00)¶ 0.80 ± 0.10 (n = 63) 
Phosphate (mmol/L, 0.87-1.45)¶ 1.20 ± 0.20 (n = 65) 
Adjusted calcium (mmol/L, 2.20-2.60)¶ 2.40 ± 0.10 (n = 66) 
* N (%) 
† Gynaecological: breast, ovarian, endometrial, cervical; Lower gastrointestinal: small bowel, appendix, colon, sigmoid, rectal, anal; 
upper gastrointestinal: oesophageal, gastric, duodenal; hepato-pancreatobiliary: liver, pancreas, bile ducts; haematological: 
leukaemia, lymphoma; others: peritoneal, bladder, sarcoma, thyroid.  
‡ This included mucositis, graft-versus-host disease, radiation-related bowel disease, intra-abdominal collection, enterocutaneous 
fistula, malabsorption, intolerance or inability of enteral feeding. 
§ This included Clinoleic, Intralipid, Lipofundin and Triomel. 
¶ Mean ± SD 




Survival: Univariate Analyses and Cox Regression 
Overall mean survival was 30.8 weeks (95% CI 21.4-39.6) and median survival was 14 weeks (IQR 5-34). At 
the time of analysis, 88.8% had passed away, 3-month survival was 49.5% and 6-month survival was 30.8%. 
Univariate analyses are shown in Table 4. Kaplan-Meier curves for type of malignancy, HPN indication, KPS 
score, GPS, PN volume, and PN potassium content are shown in Figure 1 and for the rest of the variables in 
the Supplementary Materials (Supplementary Figures 1 and 2). Post-hoc power analyses were performed for 
the current sample size and significance level 0.05, revealing power over 80% for most predictors in the 
present sample.  
Demographics: Age and gender did not significantly predict survival (p > 0.05) (Table 2). 
Medical factors: The incidence of death in patients with upper gastrointestinal (HR = 1.75, p = 0.077) and 
‘other’ malignancies (HR = 2.11, p = 0.05) was significantly higher compared to patients with gynaecological 
malignancy. Metastatic disease, surgery, chemo-radiotherapy, or indication for HPN did not significantly 
affect survival (p > 0.05). 
Performance status and prognostic scoring: KPS score and GPS significantly predicted survival. A higher 
KPS score was associated with longer survival (median survival was 20 weeks vs 5 weeks, for KPS ≥ 50 vs 
KPS < 50 respectively; HR = 0.47, p = 0.001]. A GPS of 0 was associated with longer survival than a GPS of 
2 (median survival: 55 weeks vs 10 weeks, respectively; HR = 3.19, p = 0.006). 
Anthropometrics: Weight, height, and BMI did not significantly correlate with survival.  
Serum Biochemistry: The only significant predictors of survival were CRP (HR = 1.01, p = 0.001) and WCC 
(HR = 1.06, p = 0.011). There was a trend suggesting improved survival in patients with a serum sodium 
above 135 mmol/L (HR = 0.62, p = 0.097) and higher albumin levels (HR = 0.96, p = 0.052).  
HPN requirements. Daily PN volume and potassium content predicted overall survival. An HPN volume of 2 
L/day or more was associated with a significantly increased incidence of death (86%) compared to less than 
2 L/day (median survival: 12 vs 34 weeks, respectively). An HPN potassium of 60 mmol/day or more was 
associated with a significantly increased incidence of death (81%) compared to a potassium content less than 
60 mmol/day (median survival 10 vs 24 weeks, respectively). The type of HPN lipid (SMOFLipid (33) vs 
other) did not predict survival. 
All statistically significant predictors associated with survival at univariate analysis were entered into a 
multivariate Cox regression model (Table 2). After adjusting for confounders (PN volume and PN potassium 
content), only KPS and GPS remained significant predictors of survival, whilst HPN volume reached 
borderline significance (p = 0.087). Higher scores of KPS and lower GPS were both associated with better 
survivals. 
Spearman’s rho correlations of survival with CRP (rho = -0.484) and GPS (rho = -0.444) indicated a moderate 
association, while WCC (rho = -0.300), albumin (rho = 0.338), KPS (rho = 0.374), and PN potassium content 
(rho = -0.247) were weakly correlated with survival. All correlations were significant (p < 0.05) 
(Supplementary Table 1). 
 
Table 2. Survival times and Cox regressions.  
Variables Survival (weeks) Univariate Cox regression Multivariate Cox regression  
 Median (IQR) HR (95% CI) p HR (95% CI) p 
Demographic characteristics      
Age (years) 
   
  
< 50  16 (9-36) Ref. 
 
-- -- 
50-64 10 (5-29) 1.08 (0.66-1.77) 0.755 -- -- 








Variables Survival (weeks) Univariate Cox regression Multivariate Cox regression  
 Median (IQR) HR (95% CI) p HR (95% CI) p 
Female 16 (5-34) Ref. 
 
-- -- 
Male 11 (5-32) 1.22 (0.80-1.86) 0.358 -- -- 
Medical Factors      
Type of malignancy  
  
  
Gynaecological 14 (5-55) Ref. 
 
-- -- 
Upper Gastrointestinal 10 (4-34) 1.75 (0.94-3.26) 0.077 -- -- 
Lower Gastrointestinal 12 (9-29) 1.38 (0.80-2.40) 0.251 -- -- 
Hepatobiliary 18 (10-43) 1.21 (0.59-2.52) 0.603 -- -- 
Haematological 17 (9-48) 0.95 (0.33-2.71) 0.916 -- -- 
Other 10 (3-23) 2.11 (1.00-4.45) 0.050 -- -- 
Metastatic disease  
  
  
No 18 (9-48) Ref. 
 
-- -- 
Yes 12 (5-32) 1.38 (0.79-2.39) 0.259 -- -- 
Surgery   
  
  
No 16 (7-23) Ref. 
 
-- -- 
Yes 14 (5-36) 0.84 (0.50-1.41) 0.500 -- -- 
Chemotherapy   
  
  
No 23 (16-29) Ref. 
 
-- -- 
Yes 12 (6-35) 0.92 (0.47-1.79) 0.797 -- -- 
Radiotherapy   
  
  
No 14 (6-29) Ref. 
 
-- -- 
Yes 15 (5-69) 0.65 (0.40-1.060 0.086 -- -- 
HPN indication   
  
  
Bowel obstruction 12 (6-29) Ref. 
 
-- -- 
High output ostomy 23 (5-55) 0.88 (0.49-1.56) 0.659 -- -- 
Other 30 (9-54) 0.61 (0.31-1.230 0.170 -- -- 
Anthropometrics      
Usual weight (kg)  1.002 (0.98-1.02) 0.815 -- -- 
Height (m)  12.6 (0.53-297.49) 0.117 -- -- 
Usual BMI (kg/m2)  0.97 (0.92-1.04) 0.420 -- -- 
Weight upon starting PN (kg)  1.01 (0.99-1.04) 0.192 -- -- 
% weight loss upon starting HPN      
< 20% 14 (4-35) Ref. 
 
-- -- 
between 20% and 30% 9 (7-25) 1.02 (0.52-1.99) 0.956  -- 
≥ 30% 30 (9-103) 0.64 (0.26-1.55) 0.325  -- 
BMI (kg/m2) upon starting HPN   
  
  
BMI ≤ 18.5 15 (7-32) Ref. 
 
-- -- 
BMI > 18.5 16 (4-35) 1.03 (0.61-1.74) 0.921 -- -- 
Cancer cachexia  
  
  
No 14 (8-29) Ref. 
 
-- -- 
Yes 14 (6-35) 1.09 (0.49-2.43) 0.827 -- -- 
Weight (kg) in outpatient clinic,  
0-3 months 
 
1.02 (0.97-1.06) 0.496 -- -- 
Weight (kg) in outpatient clinic,  
3-6 months 
 
1.02 (0.97-1.06) 0.506 -- -- 
Performance status      
KPS Score    
 
  
< 50 5 (2-10) Ref. 
 
Ref.  
≥ 50 20 (9-43) 0.47 (0.30-0.75) 0.001 0.49 (0.30-0.80) 0.004 
Prognostic Scores   
 
  
GPS   
 
  




Variables Survival (weeks) Univariate Cox regression Multivariate Cox regression  
 Median (IQR) HR (95% CI) p HR (95% CI) p 
0 55 (32-62) Ref. 
 
Ref.  
1 18 (7-34) 2.00 (0.82-4.91) 0.129 1.91 (0.77-4.75) 0.162 
2 10 (3-25) 3.19 (1.39-7.32) 0.006 3.60 (1.52-8.55) 0.004 
N/A 12 (6-30) 2.26 (1.01-5.08) 0.049 2.46 (1.06-5.71) 0.036 
Serum Biochemistry      
CRP (mg/L)  1.01 (1.004-1.015) 0.001 -- -- 
WCC (x 109/L)  1.06 (1.01-1.10) 0.011 -- -- 
Albumin (g/L)  0.96 (0.91-1.000 0.052 -- -- 
Haemoglobin (g/L)  1.01 (0.99-1.03) 0.322 -- -- 
Sodium (mmol/L)  0.97 (0.90-1.04) 0.382 -- -- 
Sodium (mmol/L)   
 
  
< 135 10 (4-25) Ref. 
 
-- -- 
≥ 135 16 (6-48) 0.62 (0.36-1.09) 0.097 -- -- 
Potassium (mmol/L)  0.96 (0.60-1.56) 0.876 -- -- 
Magnesium (mmol/L)  1.32 (0.1-15.74) 0.826 -- -- 
Phosphate (mmol/L)  0.41 (0.12-1.39) 0.153 -- -- 
Adjusted calcium (mmol/L)  1.48 (0.29-7.61) 0.642 -- -- 
PN requirements   
 
  
Volume (L/day)  1.63 (1.16-2.29) 0.005 -- -- 
Volume (L/day)   
 
  
< 2 34 (5-73) Ref. 
 
Ref.  
≥ 2 12 (6-27) 1.86 (1.07-3.26) 0.029 1.66 (0.93-2.98) 0.087 
Nitrogen (g/day)  1.04 (0.96-1.12) 0.386 -- -- 
Glucose (kcal/day)  1.001 (1.000-1.001) 0.155 -- -- 
Lipid (kcal/day)  1.00 (0.99-1.001) 0.664 -- -- 
Sodium (mmol/day)  1.002 (0.998-1.005) 0.332 -- -- 
Potassium (mmol/day)  1.009 (1.001-1.016) 0.025 -- -- 
Potassium (mmol/day)   
 
  
< 60 24 (9-55) Ref. 
 
Ref.  
≥ 60 10 (4-20) 1.81 (1.19-2.75) 0.006 1.41 (0.90-2.22) 0.138 
Calcium (mmol/day)  0.99 (0.90-1.08) 0.775 -- -- 
Magnesium (mmol/day)  1.03 (0.99-1.07) 0.103 -- -- 
Phosphate (mmol/day)  1.02 (1.00-1.04) 0.106 -- -- 
Type of PN lipid   
 
  
Other 12 Ref. 
 
-- -- 









Figure 1. Kaplan-Meier curves for type of malignancy, HPN indication, KPS score, GPS, PN volume, and 
PN potassium content. 
 




Karnofsky Performance Status and Glasgow Prognostic Score 
KPS was negatively correlated with GPS, CRP and WCC, and positively correlated with albumin and weight 
at 0 to 3 months. GPS was strongly positively correlated with CRP and WCC, while strongly negatively 
correlated with albumin (Supplementary Table 1). KPS score and GPS distributions by HPN indication and 
type of malignancy and metastatic disease are shown in Supplementary Table 2. No significant association 
was noted among these variables.  
 
HPN requirements 
HPN requirements were examined according to type of malignancy, HPN indication, KPS score and GPS 
(Table 3). Our findings suggest a significant difference in PN volume according to HPN indication (p = 0.005). 
Patients with bowel obstruction or high output ostomy required higher volume than other indications (2328 
mL, 2376 mL, 1725 mL, respectively). There was a correlating trend between lower KPS scores with higher 
HPN volume requirements (2426 mL vs 2165 mL, p = 0.066). Patients with bowel obstruction needed a higher 
content in nitrogen (11 g, p = 0.003), whilst patients with KPS score over 50 required higher PN lipid contents 
(607 kcal, p = 0.021). High output ostomies led to higher HPN sodium requirements, though this association 
did not reach significance (p = 0.096). PN potassium content was significantly higher in patients with bowel 
obstruction (p < 0.0001). There was a trend towards higher HPN content of calcium in patients with 
gynaecological malignancy or with bowel obstruction (p = 0.072 and p = 0.051, respectively). 
 

























Total 2251 ± 626 11 ± 3 911 ± 304 573 ± 263 112 ± 61 58 ± 26 5 ± 2 10 ± 5 21 ± 10 
Type of malignancy          
Gynaecological 2266 ± 611 11 ± 2 878 ± 267 610 ± 267 112 ± 57 56 ± 22 5 ± 2 10 ± 6 21 ± 10 
Gastrointestinal 2231 ± 623 11 ± 3 968 ± 313 576 ± 262 112 ± 51 59 ± 25 4 ± 2 10 ± 5 22 ± 9 
Other 2290 ± 711 9 ± 3 782 ± 320 477 ± 247 114 ± 100 63 ± 40 4 ± 2 10 ± 6 17 ± 9 
p-value* 0.937 0.022 0.078 0.259 0.991 0.687 0.072 0.792 0.243 
HPN indication          
Bowel obstruction 2328 ± 586 11 ± 2 938 ± 255 588 ± 256 113 ± 54 64 ± 24 5 ± 2 10 ± 5 21 ± 9 
High output ostomy 2376 ± 679 9 ± 4 765 ± 434 551 ± 349 136 ± 98 36 ± 22 3 ± 2 10 ± 8 16 ± 11 
Other 1725 ± 556 10 ± 2 890 ± 380 537 ± 206 85 ± 46 45 ± 24 4 ± 2 9 ± 5 21 ± 9 
p-value* 0.005 0.003 0.129 0.764 0.096 <0.0001 0.051 0.721 0.147 
KPS Score           
< 50 2426 ± 638 11 ± 3 872 ± 352 475 ± 304 105 ± 41 63 ± 27 5 ± 2 10 ± 5 20 ± 10 
≥ 50 2165 ± 625 11 ± 2 948 ± 271 607 ± 230 112 ± 57 57 ± 26 4 ± 2 10 ± 5 22 ± 9 
p-value* 0.066 0.964 0.251 0.021 0.548 0.272 0.912 0.466 0.253 
GPS          
0 1952 ± 665 9 ±3 626 ± 343 501 ± 325 97 ± 42 44 ± 23 5 ± 3 6 ± 5 17 ± 10 
1 2206 ± 597 11 ±2 964 ± 251 565 ± 220 124 ± 64 51 ± 14 5 ± 2 10 ± 6 19 ± 9 
2 2203 ± 625 11 ± 3 909 ± 281 552 ± 272 95 ± 32 62 ± 28 5 ± 2 9 ± 4 22 ± 9 
N/A 2392 ± 617 11 ± 3 960 ± 307 615 ± 259 126 ± 79 62 ± 29 4 ± 2 12 ± 6 23 ± 11 
p-value* 0.201 0.058 0.013 0.570 0.105 0.122 0.156 0.020 0.278 
* p-values are from ANOVA for type of malignancy, HPN indication and GPS and from t-test for KPS score. Values are presented as mean ± SD. 






We analysed the largest cohort of UK patients with advanced cancer on HPN, and examined whether survival 
might be predicted by demographic characteristics, medical factors, anthropometrics and nutritional status, 
serum blood tests, daily PN requirements, performance status and prognostic scores. Most patients required 
daily HPN (93.4%). Higher daily volume and potassium requirements were associated with a worse prognosis 
while demographic and anthropometric characteristics did not predict survival. Interestingly, upper 
gastrointestinal malignancies were associated with borderline significance for higher mortality. Only CRP and 
WCC appeared to be significant predictors of survival whereas serum albumin and sodium showed borderline 
significance. These findings offer potential prognostic parameters to assist multidisciplinary teams in decision 
making and appropriate care planning. Predictable requirements might facilitate the use of off-the-shelf PN 
bags enabling faster discharge from hospital and ultimately the provision of a sustainable service despite the 
growing number of referrals. 
Multivariate analysis identified only baseline KPS score and GPS as significant predictors of survival (2, 3, 
6, 11, 19, 34-39). In a meta-analysis, Naghibi, Smith and Elia (6) reported that patients with a higher 
performance status (defined as KPS greater than 50) survived longer than those with a KPS score less than 50 
(median survival 183 days vs 91 days, respectively) (40). Bozzetti et al. (3, 25) described that GPS 
significantly correlated with three- and sixth-month survival (p = 0.001) and included a nomogram for 
predicting survival in HPN patients with advanced cancer (25, 41-44). Our results suggest that appropriate 
timely referral of advanced cancer patients for HPN should be promoted and encouraged among healthcare 
professionals as there seems to be a window of opportunity before a decline in performance status might 
nullify the beneficial effect of HPN and inappropriate therapies in vulnerable patients (31, 45). 
The overall median length of survival in our cohort of patients receiving HPN was 14 weeks, consistent with 
the ESPEN guidelines of expected survival longer than 8-12 weeks, confirming appropriate indication for 
HPN (1, 27). Median duration of HPN in our study was 12.9 weeks consistent with reports from systematic 
reviews of 15 weeks (26). Finally, our study supports the hypothesis that a systemic inflammatory status, as 
assessed with higher GPS, CRP, and WCC is associated with a worse performance status (i.e. lower KPS 
score) and prognosis (9, 32). 
Although cancer cachexia was prevalent in our cohort of patients, anthropometric characteristics failed to 
predict survival. According to the grading system by Martin et al. (10), the majority of our patients belonged 
to grade 4 (which predicts median survival 4.9 months). Intervention at this point is unlikely to improve cancer 
cachexia but rather offer the patient comfort during end of life at home rather than in hospital. This is a 
paramount aspect for the patients and their families and should be taken into consideration in decision making 
with realistic goals of the benefit of HPN in a sustainable and ethically correct process. It also has positive 
financial consequences in terms of healthcare system costs in palliative and end of life care. In our cohort, 
most patients supported with HPN, passed away in their homes or hospice (77.9%) rather than in hospital.  
This study has several limitations. Firstly, there is the possibility of collection and selection bias due to missing 
data. Nevertheless, this would be minimal in our study due to a sufficiently large sample size (over 100 
subjects). Secondly, as a tertiary referral centre and intestinal failure unit, UCLH’s practices might be 
significantly different compared to other hospitals without seamless access to HPN services. Finally, discharge 
date was used as time point for measuring variables while other research groups have used date when PN was 
commenced in hospital (usually 2-4 weeks earlier than discharge) (6). 
In conclusion, the present study supports the use of HPN in patients with advanced cancer and offers practical 
tools to assist clinical teams in decision making. It shows that patients supported with HPN are likely to die at 
home or hospice rather than in hospital. What is apparent is the need for timely referral, since patients with 




earlier stage disease will likely have better GPS and KPS score which are associated with improved overall 
survival. Further education of healthcare professionals is necessary to ensure timely access to HPN for all 
patients with incurable cancer with an appropriate indication. Further research is needed regarding prognostic 
factors and quality of life in advanced cancer patients on HPN as well as the perception and experience of 
these patients and their families. It is imperative that HPN is used appropriately as part of an integrated 
sustainable palliative care plan.  
 
Acknowledgements and notes 
This study did not receive any funding. The authors would like to acknowledge the assistance of the following 
individuals during this research: Alastair Forbes, Shola Ajibodu, Simon O’Callaghan, Mark Samaan, Dariush 
Sadigh, Ivana Barnova, Sarah Obbard, Krista Murray, Lisa Smith, Michelle Babington, Emma Paulon, 
Klaartje (Bel) Kok. The authors also acknowledge the constructive feedback received from the reviewers 
which improved greatly the present paper. Financial Disclosure: The authors have no financial disclosure or 
conflict of interest to declare. 
 
Mailing address for reprints 
Dr Farooq Rahman 
GI Services, University College London Hospitals 
250 Euston Road, London NW1 2PG, United Kingdom 
Tel. +44 (0) 20 3456 7890 Ext 79311; Fax: +44 (0) 20 3447 9217 















1 Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al.: ESPEN guidelines on nutrition in cancer 
patients. Clinical Nutrition, 2016. doi: 10.1016/j.clnu.2016.07.015 
2 Muscaritoli M, Molfino A, Laviano A, Rasio D, Rossi Fanelli F: Parenteral nutrition in advanced cancer 
patients. Crit Rev Oncol Hematol 84, 26-36, 2012. doi: 10.1016/j.critrevonc.2012.01.005 
3 Bozzetti F, Santarpia L, Pironi L, Thul P, Klek S, et al.: The prognosis of incurable cachectic cancer patients on 
home parenteral nutrition: A multi-centre observational study with prospective follow-up of 414 patients. Annals of 
Oncology 25, 487-493, 2014. doi: 10.1093/annonc/mdt549 
4 Bukki J, Unterpaul T, Nubling G, Jox RJ, Lorenzl S: Decision making at the end of life--cancer patients' and 
their caregivers' views on artificial nutrition and hydration. Support Care Cancer 22, 3287-99, 2014. doi: 
10.1007/s00520-014-2337-6 
5 Bozzetti F: Nutrition, hydration, and patient’s preferences at the end of life. Supportive Care in Cancer 23, 
1487-1488, 2015. doi: 10.1007/s00520-014-2591-7 
6 Naghibi M, Smith TR, Elia M: A systematic review with meta-analysis of survival, quality of life and cost-
effectiveness of home parenteral nutrition in patients with inoperable malignant bowel obstruction. Clin Nutr 34, 825-
37, 2015. doi: 10.1016/j.clnu.2014.09.010 
7 Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, et al.: ESPEN Guidelines on Parenteral 
Nutrition: non-surgical oncology. Clin Nutr 28, 445-54, 2009. doi: 10.1016/j.clnu.2009.04.011 
8 Aapro M, Arends J, Bozzetti F, Fearon K, Grunberg SM, et al.: Early recognition of malnutrition and cachexia 
in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol 25, 1492-9, 2014. doi: 
10.1093/annonc/mdu085 
9 Fearon KC, Voss AC, Hustead DS, Cancer Cachexia Study G: Definition of cancer cachexia: effect of weight 
loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83, 1345-50, 
2006 
10 Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, et al.: Diagnostic criteria for the classification of 
cancer-associated weight loss. J Clin Oncol 33, 90-9, 2015. doi: 10.1200/JCO.2014.56.1894 
11 Bozzetti F: Nutritional support of the oncology patient. Crit Rev Oncol Hematol 87, 172-200, 2013. doi: 
10.1016/j.critrevonc.2013.03.006 
12 Bukki J: Re: recommendations for bowel obstruction with peritoneal carcinomatosis by laval et Al. J Pain 
Symptom Manage 48, e5-6, 2014. doi: 10.1016/j.jpainsymman.2014.07.006 
13 Soo I, Gramlich L: Use of parenteral nutrition in patients with advanced cancer. Appl Physiol Nutr Metab 33, 
102-6, 2008. doi: 10.1139/H07-152 
14 Mirhosseini M, Fainsinger R: Parenteral nutrition in patients with advanced cancer #190. J Palliat Med 12, 260-
1, 2009. doi: 10.1089/jpm.2009.9653 
15 Laval G, Marcelin-Benazech B, Guirimand F, Chauvenet L, Copel L, et al.: Recommendations for bowel 
obstruction with peritoneal carcinomatosis. J Pain Symptom Manage 48, 75-91, 2014. doi: 
10.1016/j.jpainsymman.2013.08.022 
16 Baxter JP, McKee RF: The Scottish home parenteral nutrition managed clinical network: one year on. Clin Nutr 
22, 501-4, 2003 
17 King LA, Carson LF, Konstantinides N, House MS, Adcock LL, et al.: Outcome assessment of home parenteral 
nutrition in patients with gynecologic malignancies: what have we learned in a decade of experience? Gynecol Oncol 
51, 377-82, 1993. doi: 10.1006/gyno.1993.1307 
18 Aria Guerra E, Cortes-Salgado A, Mateo-Lobo R, Nattero L, Riveiro J, et al.: Role of Parenteral Nutrition in 
Oncologic Patients with Intestinal Occlusion and Peritoneal Carcinomatosis. Nutr Hosp 32, 1222-7, 2015. doi: 
10.3305/nh.2015.32.3.9184 




19 Scolapio JS, Fleming CR, Kelly DG, Wick DM, Zinsmeister AR: Survival of Home Parenteral Nutrition-
Treated Patients: 20 Years of Experience at the Mayo Clinic. Mayo Clinic Proceedings 74, 217-222, 1999. doi: 
10.4065/74.3.217 
20 Bozzetti F, Cozzaglio L, Biganzoli E, Chiavenna G, De Cicco M, et al.: Quality of life and length of survival in 
advanced cancer patients on home parenteral nutrition. Clin Nutr 21, 281-8, 2002 
21 Duerksen DR, Ting E, Thomson P, McCurdy K, Linscer J, et al.: Is there a role for TPN in terminally ill patients 
with bowel obstruction? Nutrition 20, 760-763, 2004. doi: 10.1016/j.nut.2004.05.010 
22 Hoda D, Jatoi A, Burnes J, Loprinzi C, Kelly D: Should patients with advanced, incurable cancers ever be sent 
home with total parenteral nutrition? Cancer 103, 863-868, 2005. doi: 10.1002/cncr.20824 
23 Brard L, Weitzen S, Strubel-Lagan SL, Swamy N, Gordinier ME, et al.: The effect of total parenteral nutrition 
on the survival of terminally ill ovarian cancer patients. Gynecologic Oncology 103, 176-180, 2006. doi: 
10.1016/j.ygyno.2006.02.013 
24 Chermesh I, Mashiach T, Amit A, Haim N, Papier I, et al.: Home parenteral nutrition (HTPN) for incurable 
patients with cancer with gastrointestinal obstruction: Do the benefits outweigh the risks? Medical Oncology 28, 83-88, 
2011. doi: 10.1007/s12032-010-9426-2 
25 Bozzetti F, Cotogni P, Lo Vullo S, Pironi L, Giardiello D, et al.: Development and validation of a nomogram to 
predict survival in incurable cachectic cancer patients on home parenteral nutrition. Annals of Oncology 26, 2335-2340, 
2015. doi: 10.1093/annonc/mdv365 
26 Fragkos K, Fini L, Keane N, Kwok H, Paulon E, et al.: PTU-109 Home parenteral nutrition in patients with 
advanced cancer: a systematic review. Gut 66, A104-A105, 2017. doi: 10.1136/gutjnl-2017-314472.204 
27 Staun M, Pironi L, Bozzetti F, Baxter J, Forbes A, et al.: ESPEN Guidelines on Parenteral Nutrition: home 
parenteral nutrition (HPN) in adult patients. Clin Nutr 28, 467-79, 2009. doi: 10.1016/j.clnu.2009.04.001 
28 Pironi L, Ruggeri E, Tanneberger S, Giordani S, Pannuti F, et al.: Home artificial nutrition in advanced cancer. 
Journal of the Royal Society of Medicine 90, 597-603, 1997 
29 Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH: The use of the nitrogen mustards in the palliative 
treatment of carcinoma.With particular reference to bronchogenic carcinoma. Cancer 1, 634-656, 1948. doi: 
10.1002/1097-0142(194811)1:4<634::aid-cncr2820010410>3.0.co;2-l 
30 Schag CC, Heinrich RL, Ganz PA: Karnofsky performance status revisited: reliability, validity, and guidelines. 
J Clin Oncol 2, 187-93, 1984 
31 Hui D: Prognostication of Survival in Patients With Advanced Cancer: Predicting the Unpredictable? Cancer 
Control 22, 489-97, 2015 
32 Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, et al.: Definition and classification of cancer cachexia: an 
international consensus. The Lancet Oncology 12, 489-495, 2011. doi: 10.1016/s1470-2045(10)70218-7 
33 Tian H, Yao X, Zeng R, Sun R, Tian H, et al.: Safety and efficacy of a new parenteral lipid emulsion (SMOF) 
for surgical patients: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 71, 815-21, 2013. 
doi: 10.1111/nure.12053 
34 Evans C, McCarthy M: Prognostic uncertainty in terminal care: can the Karnofsky index help? Lancet 1, 1204-
6, 1985 
35 Matsunuma R, Tanbo Y, Asai N, Ohkuni Y, Watanabe S, et al.: Prognostic factors in patients with terminal 
stage lung cancer. J Palliat Med 17, 189-94, 2014. doi: 10.1089/jpm.2013.0448 
36 Schonwetter RS, Robinson BE, Ramirez G: Prognostic factors for survival in terminal lung cancer patients. J 
Gen Intern Med 9, 366-71, 1994 
37 Vigano A, Dorgan M, Buckingham J, Bruera E, Suarez-Almazor ME: Survival prediction in terminal cancer 
patients: a systematic review of the medical literature. Palliat Med 14, 363-74, 2000 
38 Keane N, Fragkos KC, Patel PS, Obbard S, Murray K, et al.: MON-P068: An Updated Audit of Home Parenteral 
Nutrition (HPN) in Palliative Oncology Patients - A UK Single Centre Case Series with Survival Analysis. Clinical 
Nutrition 35, S178, 2016. doi: 10.1016/s0261-5614(16)30702-6 
39 Glare P, Sinclair C, Downing M, Stone P, Maltoni M, et al.: Predicting survival in patients with advanced 
disease. Eur J Cancer 44, 1146-56, 2008. doi: 10.1016/j.ejca.2008.02.030 




40 McMillan DC: The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients 
with cancer. Cancer Treat Rev 39, 534-40, 2013. doi: 10.1016/j.ctrv.2012.08.003 
41 Brown DJ, Milroy R, Preston T, McMillan DC: The relationship between an inflammation-based prognostic 
score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and 
gastrointestinal cancer. J Clin Pathol 60, 705-8, 2007. doi: 10.1136/jcp.2005.033217 
42 Proctor MJ, Talwar D, Balmar SM, O'Reilly DS, Foulis AK, et al.: The relationship between the presence and 
site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow 
Inflammation Outcome Study. Br J Cancer 103, 870-6, 2010. doi: 10.1038/sj.bjc.6605855 
43 Pantano Nde P, Paiva BS, Hui D, Paiva CE: Validation of the Modified Glasgow Prognostic Score in Advanced 
Cancer Patients Receiving Palliative Care. J Pain Symptom Manage 51, 270-7, 2016. doi: 
10.1016/j.jpainsymman.2015.09.010 
44 Douglas E, McMillan DC: Towards a simple objective framework for the investigation and treatment of cancer 
cachexia: the Glasgow Prognostic Score. Cancer Treat Rev 40, 685-91, 2014. doi: S0305-7372(13)00260-0 [pii] 
10.1016/j.ctrv.2013.11.007 
45 Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, et al.: Prognostic factors in advanced cancer 
patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for 
Palliative Care. J Clin Oncol 23, 6240-8, 2005. doi: 10.1200/JCO.2005.06.866 
 
 







Supplementary Table 1. Spearman correlations between variables. Only correlations with p < 0.05 
are shown. Censored cases were not included in this analysis. 
Variable 1 Variable 2 Spearman’s rho p N 
Survival  CRP (mg/L) -0.484 <0.001 55 
Survival  WCC (x 109/L) -0.300 0.027 54 
Survival  Albumin (g/L) 0.338 0.012 55 
Survival  PN Potassium (mmol/day) -0.247 0.016 94 
Survival  KPS Score 0.374 <0.001 88 
Survival  GPS -0.444 0.001 55 
KPS Score  Age  -0.276 0.010 87 
KPS Score  Weight in clinic, months 0-3 0.401 0.031 29 
KPS Score  CRP (mg/L) -0.329 0.017 52 
KPS Score  WCC (x 109/L) -0.523 <0.001 51 
KPS Score  Albumin (g/L) 0.288 0.038 52 
KPS Score  Haemoglobin (g/L) -0.294 0.038 50 
KPS Score  PN Phosphate (mmol/day) 0.230 0.032 87 
KPS Score  GPS -0.281 0.043 52 
GPS CRP (mg/L) 0.703 <0.001 55 
GPS WCC (x 109/L) 0.529 <0.001 54 
GPS Albumin (g/L) -0.683 <0.001 55 
 
Supplementary Table 2. KPS score and GPS distribution according to type of malignancy, 
metastasis, and HPN indication. 
 KPS Score GPS  
 < 50 ≥ 50 p* 0 1 2 N/A p* 
Type of 
malignancy 
        
Gynaecological 9 (25.7%) 26 (74.3%) 0.931 4 (10.8%) 7 (18.9%) 11 (29.7%) 15 (40.5%) 0.968 
Gastrointestinal 15 (29.4%) 36 (70.6%)  4 (7.3%) 10 (18.2%) 20 (36.4%) 21 (38.2%)  
Other 4 (28.6%) 10 (71.4%)  2 (13.3%) 2 (13.3%) 6 (40.0%) 5 (33.3%)  
Metastasis         
No 4 (21.1%) 15 (78.9%) 0.454 3 (15.0%) 2 (10.0%) 8 (40.0%) 7 (35.0%) 0.582 
Yes 24 (21.1%) 57 (70.4%)  7 (8.0%) 17 (19.5%) 29 (33.3%) 34 (39.1%)  
Indication for HPN         
Bowel Obstruction 21 (29.2%) 51 (70.8%) 0.820 5 (6.4%) 13 (16.7%) 27 (34.6%) 33 (42.3%) 0.430 
High output 
ostomy 
3 (21.4%) 11 (78.6%)  2 (13.3%) 4 (26.7%) 5 (33.3%) 4 (26.7%)  
Other 3 (25.0%) 9 (75.0%)  3 (25.0%) 2 (16.7%) 3 (25.0%) 4 (33.3%)  
* p-values are from chi-square test. 
  





Supplementary Figure 1. Kaplan-Meier Curve for age, gender, type of malignancy, metastasis, 
surgery, and chemotherapy. 
  




Supplementary Figure 2. Kaplan-Meier Curve for radiotherapy, weight loss, BMI, cancer cachexia, 
parenteral nutrition lipid, and serum sodium. 
 
 
